A systematic review and meta-analysis of efficacy and safety of Calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
CONCLUSION: Calcimimetic agents can reduce the PTH level, Ca level, P level, calcium-phosphorus product level and do not increase the serious adverse events.PMID:36305135 | DOI:10.2174/1381612829666221027110656
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Yiping Liu Qian Yang Guangyong Chen Tianbiao Zhou Source Type: research
More News: Calcium | Chronic Kidney Disease | Chronic Pain | Databases & Libraries | Dialysis | Drugs & Pharmacology | Gastroenterology | Hormones | Hyperparathyroidism | Pain | Parathyroidectomy | Phosphorus | Science | Sensipar | Study | Urology & Nephrology